World Journal of Pharmaceutical Science and Research

www.wjpsronline.com

Review Article

ISSN: 2583-6579
SJIF Impact Factor: 6.916
Year - 2026
Volume: 5; Issue: 5
Page: 507-525

A COMPREHENSIVE REVIEW ON ANTICANCER EFFECT OF VITAMIN C ON SPECIFIC CANCER

Rakesh Kumar Sahu*[1], Gautam Kumar[2], Gulshan Kumar[3], Rohit Kumar[4], Jaikee Kumar[5], M. D. Akhtar Hussain[6], Anil Kumar[7], Deepak[8]

[1]Assistant Professor, Mahadeva Lal Schroff College of Pharmacy Aurangabad Bihar-824102.

[2-8]B. Pharm Final Year Students, Mahadeva Lal Schroff College of Pharmacy Aurangabad, Bihar-824102.

Article Received: 17 March 2026 | | ***Article Revised: 8 April 2026*** | | ***Article Accepted: 28 April 2026***

***Corresponding Author: Rakesh Kumar Sahu**
Assistant Professor, Mahadeva Lal Schroff College of Pharmacy Aurangabad Bihar-824102.
DOI: https://doi.org/10.5281/zenodo.19997379

How to cite this Article: Rakesh Kumar Sahu, Gautam Kumar, Gulshan Kumar, Rohit Kumar, Jaikee Kumar, M. D. Akhtar Hussain, Anil Kumar, Deepak (2026) A COMPREHENSIVE REVIEW ON ANTICANCER EFFECT OF VITAMIN C ON SPECIFIC CANCER. World Journal of Pharmaceutical Science and Research, 5(5), 507-525.

ABSTRACT

While long valued as a simple antioxidant, vitamin C is now being seriously re-evaluated as a powerful tool in cancer treatment. Recent studies show that when administered in high-dose intravenous forms, it can achieve blood levels that trigger the production of hydrogen peroxide within tumors, effectively killing cancer cells while protecting healthy ones. Beyond this direct attack, it helps regulate the immune system and works alongside traditional therapies like chemotherapy to improve outcomes. This approach has shown particular promise in treating aggressive cancers—such as lung, breast, and colorectal varieties—especially those involving specific genetic mutations like KRAS or BRAF. Beyond its direct attack on cancer cells, vitamin C helps repair the body's internal "programming" by activating enzymes that turn back on important tumor-suppressing genes. It also toughens the area surrounding a tumor, making it harder for cancer to spread, while simultaneously coaching the immune system to better hunt and destroy malignant cells. Data shows that people with diets high in vitamin C often have lower rates of breast and stomach cancers. Most importantly, early clinical trials indicate that adding high-dose vitamin C to standard treatments is safe, helps patients feel better during therapy, and may even help them live longer. Even with this progress, several hurdles remain. There is ongoing debate regarding how the body processes vitamin C, the best way to dose it, and how it interacts with other medications. Some trials have shown mixed results, which might be due to differences in how the studies were designed or the specific types of patients involved. To address this, current research is focused on finding better ways to use vitamin C, such as using nanotechnology for delivery or identifying specific "biomarkers" to predict which patients will benefit most. Ultimately, while more large-scale studies are needed to settle these controversies, the growing evidence suggests that vitamin C could become a safe and accessible addition to modern, multi-step cancer treatments.

KEYWORDS: Vitamin C, Ascorbic acid, cancer therapy, tumour microenvironment, apoptosis, epigenetics.

1. INTRODUCTION

Cancer persists as a pervasive and complex global health challenge, imposing a massive financial and physical toll on society. The disease originates when the body's regulatory mechanisms for cellular replication fail, leading to the erratic and harmful proliferation of abnormal cells. Driven by damage to the DNA—the genetic material governing cellular function—these cells bypass natural growth limits, continuously dividing and causing cumulative physiological harm.[1] Given that conventional treatments often face hurdles like systemic toxicity, drug resistance, and high rates of recurrence, the medical community is aggressively pursuing novel therapeutic alternatives. Within this search, vitamin C (ascorbic acid) has seen a significant revival in clinical interest, as its unique pharmacological and biochemical properties offer promising potential for both cancer prevention and adjunctive care.[2]

Vitamin C is deeply intertwined with cancer prevention, progression, and therapy, functioning either through its standard biological properties or as a potent pro-oxidant at elevated concentrations.[3] The concept of using vitamin C as a therapeutic agent dates back nearly fifty years to clinical reports suggesting extended survival in terminally ill patients treated with high-dose intravenous and oral doses.[4,5] However, these early results were initially dismissed after subsequent randomized trials—which focused primarily on oral administration—failed to show significant benefits, underscoring the critical role of pharmacokinetics in its efficacy.[6,7]

Anti-tumor mechanisms

Studies have revealed that its anti-cancer effects are mediated by regulating oxidative stress, epigenetic modifications, signaling pathways, and immune responses (Fig. 1). The following sections will provide a detailed exploration of these mechanisms to elucidate the potential applications of vitamin C in cancer treatment.[8]



Figure 1: The Anti-Tumor Mechanism Of High-Dose Vitamin C.

Clinical and Epidemiological Impact

Broad epidemiological data and comprehensive reviews have consistently linked higher dietary vitamin C intake to a reduced risk of various cancers, specifically those of the breast, bladder, and colon.[9] In a clinical setting, it is increasingly recognized not just for prevention, but as an adjunctive therapy that can mitigate the side effects of chemotherapy, enhance patient quality of life, and increase the sensitivity of tumors to standard treatments.[10]

Despite this promise, significant hurdles remain, particularly regarding the standardization of dosages, the selection of appropriate patient groups, and the full mapping of its dual biological roles.[11] Consequently, there is an urgent need for rigorous reviews to synthesize current evidence. This article intends to provide a holistic overview of the recent literature, bridging the gap between historical debates and modern breakthroughs while exploring the future of vitamin C in oncology.

2. Biochemical Properties of Vitamin C

Vitamin C (ascorbic acid) is a versatile, water-soluble molecule characterized by its ability to donate electrons, a feature that allows it to function as both a protective antioxidant and a vital enzymatic cofactor.[12] Under normal physiological conditions, it neutralizes reactive oxygen species (ROS), shielding essential biomolecules like DNA and proteins from oxidative stress, which is a primary mechanism in cancer prevention.[13].

Beyond its role as an antioxidant, vitamin C is essential for the function of various monooxygenase and dioxygenase enzymes.[14] By keeping the metal centers of these enzymes in a reduced state, it facilitates the synthesis of collagen, carnitine, and key neurotransmitters such as catecholamines.[15,16]

Pharmacokinetics and Therapeutic Action

The impact of vitamin C is heavily dictated by how it is administered:

- Oral Intake: Regulated by sodium-dependent transporters (SVCT1 and SVCT2), oral doses rarely exceed plasma concentrations of 0.2 mM.[17]
- Intravenous (IV) Administration: IV delivery bypasses these metabolic "ceilings," reaching levels above 1 mM. At these concentrations, vitamin C shifts from an antioxidant to a pro-oxidant, generating hydrogen peroxide in extracellular spaces to selectively target and kill tumor cells.[18]

Furthermore, vitamin C enhances the body's overall defense by recycling other antioxidants like Vitamin E and maintaining the integrity of the extracellular matrix through collagen maturation, which may help inhibit tumor invasion.[19,20,21]

Table 1: Summary of Vitamin C's Biochemical Functions.

Function	Mechanism	Relevance to Oncology
Antioxidant	Neutralizes ROS and protects lipids, proteins, and DNA.	Prevents genomic instability and oncogenic mutations.
Pro-oxidant	Generates hydrogen peroxide (H_2O_2) at high concentrations (>1 mM).	Induces selective cytotoxicity in cancer cells.
Enzymatic Cofactor	Maintains metal centers (e.g., Iron/Copper) in a reduced state.	Supports collagen synthesis and neurotransmitter balance.
Epigenetic Regulator	Acts as a cofactor for TET enzymes and histone demethylases.	Reprograms gene expression and may reverse drug resistance.
Redox Recycling	Regenerates Vitamin E from its oxidized form.	Amplifies the body's total antioxidant capacity.
Structural Support	Facilitates collagen maturation and matrix integrity.	Strengthens tissue barriers against tumor metastasis.

3. Mechanisms of Anticancer Action

The anticancer effects of vitamin C are remarkably diverse, spanning classical biochemical processes as well as sophisticated epigenetic, immunological, and microenvironmental modulations. The defining feature of its

pharmacological profile is its concentration-dependent duality: it acts as a protective antioxidant at standard levels but transitions into a cytotoxic pro-oxidant at high concentrations, primarily influenced by the route of delivery.[22]

Table 2: Primary Mechanisms of Vitamin C in Oncology.

Mechanism Category	Primary Biological Action	Anticancer Significance
Classical Biochemical	Redox switching (Antioxidant vs. Pro-oxidant)	Protects healthy cells from DNA damage at low doses; selectively kills cancer cells via H_2O_2 at high doses.
Epigenetic Regulation	Activation of TET and histone demethylases	Reprograms gene expression to restore tumor-suppressor functions and reverse drug resistance.
Immunological Modulation	Enhancement of immune cell function	Boosts the activity of T-cells and Natural Killer (NK) cells to better detect and destroy tumors.
Microenvironmental Support	Collagen maturation and stability	Strengthens the extracellular matrix, creating a physical barrier that limits tumor invasion and metastasis.

3.1 Direct Cytotoxicity through Pro-oxidant Action

When administered at pharmacological levels—specifically through intravenous delivery—vitamin C triggers direct cytotoxic effects in malignant cells by inducing significant oxidative stress.[23] Unlike healthy cells, cancer cells frequently possess impaired mitochondrial function and metabolic vulnerabilities, leaving them exceptionally defenseless against the reactive oxygen species (ROS) and hydrogen peroxide (H_2O_2) generated by vitamin C.[24] This extracellularly produced H_2O_2 infiltrates the tumor cells, causing critical DNA damage and exhausting ATP reserves, which ultimately results in programmed cell death, or apoptosis.[25]

Laboratory research has validated that high-dose vitamin C inhibits tumor growth and triggers apoptosis in a dose-dependent manner across several lineages, such as breast and colorectal cancers.[26] These lethal effects are often intensified within the tumor microenvironment itself; the presence of elevated catalytic iron levels facilitates Fenton-type reactions, which accelerate the formation of destructive free radicals and improve the overall efficiency of the treatment.[27]

Table 3: Pathway of Vitamin C-Induced Pro-oxidant Cytotoxicity.

Stage	Process	Impact on Cancer Cells
Generation	Production of extracellular H_2O_2 via high-dose Vitamin C.	Creates a high-stress oxidative environment.
Infiltration	Diffusion of H_2O_2 into the malignant cell.	Overwhelms weakened mitochondrial defenses.
Catalysis	Fenton-type reactions involving catalytic iron.	Generates highly reactive hydroxyl radicals.
Destruction	Induction of DNA damage and ATP depletion.	Triggers apoptosis and stops cell proliferation.

3.2 Modulation of Epigenetic Regulation

In addition to its role in redox biology, vitamin C functions as a vital cofactor for TET (ten-eleven translocation) methylcytosine dioxygenases and Jumonji-C domain-containing histone demethylases. These enzymes are the primary drivers of DNA demethylation and the modification of histones, which control how genetic information is accessed.[28]

By supporting these processes, vitamin C helps restore genomic stability; it can effectively "turn back on" tumor suppressor genes that were silenced by the cancer and encourage malignant cells to return to normal differentiation pathways.[29] Furthermore, recent research indicates that vitamin C can act synergistically with DNA methyltransferase inhibitors, significantly boosting treatment efficacy in specific types of blood cancers (hematological malignancies).[30]

Table 4: Epigenetic Impact of Vitamin C on Cancer Cells.

Component	Biochemical Action	Resulting Effect
TET Enzymes	Promotes DNA demethylation.	Reverses silencing of tumor suppressor genes.
Jumonji-C Domain	Facilitates histone demethylation.	Reorganizes chromatin structure for genomic stability.
Differentiation	Reinitiates normal cellular pathways.	Stops the aggressive, immature growth of cancer cells.
Synergy	Pairs with methyltransferase inhibitors.	Enhances clinical outcomes in hematological cancers.

3.3 Immune System Modulation

Vitamin C is increasingly recognized for its role as an immunomodulatory agent, significantly boosting the body's natural defenses against malignancy. It enhances the activity of cytotoxic T lymphocytes and natural killer (NK) cells, while simultaneously working to dismantle the immune-suppressing tactics often employed by tumors.[31] By altering cytokine profiles and fortifying the anti-tumor response directly within the tumor microenvironment, vitamin C facilitates the more efficient identification and clearance of malignant cells.[32]

Table 5: Immunomodulatory Effects of Vitamin C in Oncology.

Target Component	Biological Influence	Oncological Benefit
Cytotoxic T Cells	Enhances activation and proliferation.	Increases direct destruction of tumor cells.
Natural Killer (NK) Cells	Boosts functional capacity and surveillance.	Improves detection of early-stage malignant changes.
Cytokine Profiles	Modulates signaling molecule production.	Shifts the environment from pro-tumor to anti-tumor.
Microenvironment	Reduces tumor-associated immune suppression.	Prevents cancer cells from "hiding" from the immune system.

3.4 Impact on Tumour Microenvironment

Vitamin C plays a critical role in stabilizing the extracellular matrix, which serves as the structural framework surrounding cells. By strengthening this physical barrier, it potentially restricts the ability of cancer cells to invade neighboring tissues and metastasize to distant organs.[33] When this structural reinforcement is combined with vitamin C's ability to trigger pro-oxidant cytotoxicity and induce epigenetic reprogramming, it creates a profoundly hostile environment for even the most resistant cancer cells.

Table 6: Vitamin C and the Tumour Microenvironment (TME).

Action	Biological Mechanism	Consequence for Cancer
Matrix Stabilization	Enhances collagen synthesis and cross-linking.	Hinders physical invasion and metastatic spread.
Synergistic Hostility	Combines structural, chemical, and genetic pressures.	Limits the survival of therapy-resistant cell populations.
Environmental Stress	Increases oxidative pressure within the TME.	Selectively targets cancer cells while sparing healthy tissue.

4. Vitamin C and Cancer Prevention

Research into vitamin C as a preventive agent has yielded a significant body of evidence, with population studies generally linking high dietary intake to a lower risk of several malignancies, including those of the respiratory, digestive, and urinary tracts.[34] Early landmark reviews indicated that high consumption of vitamin C could lead to an approximately twofold risk reduction for non-hormone-dependent cancers, such as those of the esophagus, larynx, and pancreas.[35] These findings suggest that vitamin C may work in tandem with other natural compounds in fruits and vegetables to bolster the body's defenses.

Recent large-scale umbrella reviews have confirmed these trends, finding consistent inverse relationships between vitamin C intake and the development of bladder, breast, lung, and colorectal cancers.[36] Interestingly, these protective benefits are more pronounced when the nutrient is obtained from whole foods rather than isolated supplements, pointing to the importance of the "food matrix". Dose-response analyses further suggest a linear benefit; for example, every 100 mg/day increase in intake has been linked to a 7% reduction in lung cancer risk, though results can vary based on geography and study design.[37]

Despite these positive observational findings, the use of supplements remains a point of contention. Meta-analyses of randomized controlled trials (RCTs) have often failed to show that vitamin C pills provide the same preventive benefits as a vitamin-rich diet.[38] This gap between diet and supplementation may be due to complex nutrient interactions, bioavailability issues, or individual genetic differences in how the body transports the vitamin.[39,40]

Table 7: Summary of Vitamin C in Cancer Prevention.

Cancer Category	Observed Effect	Evidence Source
Respiratory & Oral	Reduced risk of lung, laryngeal, and oral cavity cancers; 7% risk drop per 100mg/day.	Block (1991); [35, 37]
Gastrointestinal	Significant protection for esophageal, gastric, and colorectal cancers.	Chen et al. (2022); [36, 38]
Hormone-Related	Lower incidence of breast and cervical cancers.	[35, 36]
Urogenital	Protective associations noted for bladder and renal cancers.	[34, 36]
Dietary vs. Supplement	Natural food sources show higher efficacy than isolated supplements.	Lee et al. (2015); [39, 40]

5. Clinical Evidence and Therapeutic Applications

Clinical research regarding vitamin C in oncology has matured significantly, moving past basic safety assessments to rigorous randomized trials. These studies focus on pharmacological ascorbate—high-dose intravenous (IV) vitamin C—used alongside standard cancer treatments. Unlike oral intake, IV delivery achieves the millimolar plasma concentrations necessary to trigger tumor-selective pro-oxidant effects, effectively turning the vitamin into a targeted anticancer tool.

In patients with solid tumors, including ovarian and pancreatic cancers, glioblastoma, and non-small cell lung cancer, this approach has shown consistent benefits. Notably, IV ascorbate has been found to lower the toxic side effects of chemotherapy, helping patients maintain a better quality of life. Furthermore, some randomized trials have reported extended overall and progression-free survival, all while maintaining a strong safety profile. These positive signals have paved the way for larger Phase II and III clinical trials and the development of biomarkers to identify which patients will benefit most.

Table 8: Therapeutic Impact of Intravenous (IV) Pharmacological Ascorbate.

Clinical Parameter	Observed Outcome	Impact on Patient Care
Pharmacokinetics	Achieves millimolar plasma levels.	Enables tumor-selective pro-oxidant cytotoxicity.
Tolerability	Consistent safety even at high doses.	Does not increase the burden of adverse events.
Chemotherapy Support	Reduced systemic toxicity.	Mitigates harsh side effects of standard regimens.
Survival Metrics	Improved overall and progression-free survival.	Demonstrated efficacy in selected randomized settings.
Tumor Applications	Effective in Ovarian, Pancreatic, and Lung cancers.	Versatile adjunct for various solid tumor types.

5.1. Route, Dosing, and Pharmacokinetics

The efficacy of vitamin C in cancer treatment is primarily determined by its delivery method. Clinical pharmacology indicates that oral consumption is incapable of reaching the concentrations necessary for tumor-selective destruction. In contrast, intravenous (IV) pharmacological ascorbate can consistently elevate plasma levels to the 10–20 mM range. This high concentration is the threshold required to trigger the production of extracellular hydrogen peroxide within the tumor microenvironment.

Initial human trials and dose-escalation studies have established a standardized dosing window. Administering approximately 75–87.5 g per infusion, two to three times per week, is sufficient to maintain therapeutic plasma levels. Research suggests that doses exceeding 100 g provide diminishing returns, making the 75–87.5 g range the benchmark for combination therapies involving chemotherapy and radiation. A recent randomized trial focusing on metastatic pancreatic ductal adenocarcinoma (PDAC) confirmed that a 75 g dose given thrice weekly successfully reached the targeted millimolar concentrations without increasing patient side effects, proving that these high-dose schedules are both safe and practical for standard oncological care.

Table 9: Pharmacokinetic Profile: Oral vs. Intravenous Administration.

Feature	Oral Administration	Intravenous (IV) Administration
Plasma Concentration	Low (typically <0.2 mM)	High (reaches **10–20 mM**)
Mechanism of Action	Purely antioxidant	Transitions to **pro-oxidant** (cytotoxic)
Standard Dosage	Daily supplements	**75–87.5 g** per infusion
Frequency	Daily	2–3 times per week
Tumor Impact	Minimal direct cytotoxicity	Generates H_2O_2 in the tumor environment
Clinical Feasibility	High	Confirmed safe in routine oncology schedules

5.2. Solid Tumors: Efficacy Signals and Disease-Specific Data

Clinical evidence across various aggressive malignancies indicates that intravenous (IV) vitamin C acts as a powerful synergist, enhancing the effects of standard treatments while simultaneously protecting patients from severe side effects.

- Ovarian Cancer: Research published in Science Translational Medicine found that adding high-dose IV ascorbate to carboplatin and paclitaxel significantly lowered chemotherapy-related toxicities (grades 1–2) without reducing the drugs' effectiveness. Mechanistically, the ascorbate triggered DNA damage and ATP depletion specifically within the ovarian cancer cells.

- Pancreatic Cancer (PDAC): In a landmark randomized trial for metastatic PDAC, the addition of 75 g of IV ascorbate to a gemcitabine/nab-paclitaxel regimen nearly doubled median overall survival (16.0 months vs. 8.3 months). It also significantly extended progression-free survival without increasing toxicity, providing clear validation of its clinical benefit in advanced disease.
- Glioblastoma: A Phase I trial successfully integrated 87.5 g of IV ascorbate with radiation and temozolomide. The treatment was well-tolerated and resulted in survival rates (18 months overall survival) that outperformed historical benchmarks, particularly in patients with the high-risk unmethylated MGMT promoter.
- Non-Small Cell Lung Cancer (NSCLC): Randomized Phase II data have confirmed the safety and logistical feasibility of repeated high-dose infusions in patients with advanced NSCLC, establishing a foundation for future large-scale trials involving systemic therapies.
- Prostate Cancer (mCRPC): Recent trials in metastatic castration-resistant prostate cancer demonstrated that IV vitamin C can be successfully combined with docetaxel, proving the strategy's versatility in genitourinary oncology.

Table 10: Clinical Outcomes of Adjunctive High-Dose IV Vitamin C.

Cancer Type	Standard Treatment Pair	Key Clinical Outcome	Reference/Source
Ovarian	Carboplatin + Paclitaxel	Reduced systemic toxicity; improved tolerability.	*Sci. Transl. Med.*
Pancreatic	Gemcitabine + Nab-paclitaxel	Doubled median survival (8.3 to 16.0 months).	*Redox Biology* Trial
Glioblastoma	Radiation + Temozolomide	Favorable survival in high-risk (MGMT unmethylated) groups.	Phase I Trial
NSCLC	Best Supportive Care	Confirmed safety and delivery feasibility.	Phase II Study
Prostate	Docetaxel	Integration feasibility in taxane-based regimens.	mCRPC Trial

5.3. Nano-vitamin C versus intravenous infusion

Nanotechnology represents a significant evolution in vitamin C delivery, offering distinct pharmacological benefits over traditional intravenous (IV) molecular forms. Based on the provided text, the three specific advantages and clinical implications are as follows:

Specific Advantages of Nano-Vitamin C

- Superior Stability: Encapsulation or chemical conjugation protects vitamin C from the complexities of the bloodstream. Research indicates that nanoparticle formulations undergo only approximately 5% oxidative degradation even after 10 days of storage at room temperature.
- **Enhanced Cellular Uptake:** Unlike molecular vitamin C, which relies on specific Na+-dependent and energy-dependent transporters, nano-vitamin C enters cells via endocytosis or phagocytosis. Nanoparticles smaller than 200 nm typically use clathrin-mediated endocytosis, while those larger than 500 nm enter through phagocytosis, significantly increasing total uptake efficiency.
- **Controlled and Targeted Release:** Nanoparticles can be engineered to respond to specific stimuli within the tumor microenvironment (TME), such as hypoxia, acidic pH, or abnormal blood vessels. This allows for a precision release of the nutrient directly where it is needed most.



Figure 2: The potential advantages of nano-vitamin C: i) greater stability during transport in the complex blood system; ii) improving the cellular uptake of vitamin C; and iii) achieving targeted release.

5.4. Safety, Tolerability, and Quality of Life

Clinical research across various trial phases consistently highlights the favorable safety profile of pharmacological ascorbate. When administered intravenously, side effects are generally mild and temporary—such as dry mouth or chills—with no established pattern of severe, dose-limiting toxicities. A significant benefit observed when combining high-dose vitamin C with cytotoxic chemotherapy is the reduction of treatment-related adverse effects, which suggests a protective role for healthy tissues.

Furthermore, quality-of-life assessments in randomized trials for pancreatic and ovarian cancers show that adding intravenous vitamin C does not negatively impact the patient's well-being. Instead, it often reduces the overall toxicity burden without diminishing the treatment's ability to control the disease, pointing toward its value in supportive care. Expert reviews emphasize that while the therapy is broadly safe, standardized protocols are essential. This includes mandatory screening for G6PD deficiency to prevent rare complications, ensuring that the specific pharmacological exposure required for anticancer activity is achieved safely and effectively.

5.5. Practical Integration and Ongoing Questions

The practical application of vitamin C in oncology necessitates strict adherence to standardized protocols, specifically prioritizing the intravenous route at a frequency of two to three times per week. Proper coordination with chemotherapy and radiation schedules is essential to maximize the vitamin's ability to sensitize tumors to these treatments while simultaneously tracking patient-reported outcomes and any potential cumulative toxicities.

While recent randomized trials have provided strong evidence for improved overall and progression-free survival in metastatic pancreatic cancer (PDAC), several priorities remain for the medical community. These include:

- Broad Validation: Expanding research to confirm similar survival gains across a wider variety of tumor types.
- Biomarker-Guided Selection: Identifying specific genetic or molecular markers that predict which patients will respond best to ascorbate therapy.
- Precision Frameworks: Future Phase II and III trials are encouraged to stratify patients based on tumor genomics and utilize pharmacodynamic endpoints—such as measuring actual achieved plasma levels and oxidative stress markers—to clearly connect dosage to clinical efficacy.

Ultimately, head-to-head comparisons against evolving standard-of-care treatments will be necessary to define the exact clinical role where pharmacological ascorbate provides the most significant therapeutic advantage.

6. Synergy with Conventional Therapies

When administered at pharmacological (intravenous) levels, vitamin C acts as a powerful adjuvant that boosts the effectiveness of several standard cancer treatments. This synergy is made possible through mechanisms that heighten the destruction of tumor cells while generally protecting healthy tissues. This dual action facilitates radiosensitization and chemosensitization, and emerging research suggests it may even strengthen the impact of immune checkpoint inhibitors in both laboratory and clinical environments.[41]

Mechanistic Basis for Combined Treatment

The primary driver of this collaborative effect is the achievement of high, transient plasma concentrations. These levels trigger the production of extracellular hydrogen peroxide and localized oxidative stress specifically within the tumor. This process leads to:

- Amplified DNA Damage: It compounds the genetic destruction caused by traditional genotoxic therapies like chemotherapy and radiation.
- Immune Modulation: It recalibrates the body's immune response to better recognize and attack the malignancy.
- Selectivity: These effects occur without a corresponding rise in systemic toxicity, effectively widening the therapeutic window for conventional treatments.[42]

6.1. Chemotherapy Combinations

Laboratory research has established a powerful synergy between pharmacological ascorbate and gemcitabine, showcasing increased destruction of pancreatic cancer cells and superior tumor suppression in animal models compared to using chemotherapy by itself.[43] These preclinical successes have translated into significant clinical milestones. Most notably, a randomized trial involving metastatic pancreatic ductal adenocarcinoma revealed that integrating 75 g of intravenous vitamin C three times a week with gemcitabine and nab-paclitaxel nearly doubled the median overall survival—increasing it from 8.3 to 16.0 months—while also extending progression-free survival without introducing new safety concerns.[44]

Similarly, research in ovarian cancer has demonstrated that high-dose intravenous vitamin C acts as a protective buffer. A study in Science Translational Medicine showed that when combined with carboplatin and paclitaxel, the treatment significantly reduced mild-to-moderate chemotherapy-related toxicities. This improvement in the patient's physical tolerance of the regimen occurred without diminishing the drugs' ability to attack the tumor, highlighting vitamin C’s potential to make standard intensive therapies more manageable.[45]

6.2. Radiotherapy Combinations

Pharmacological ascorbate exhibits a unique "dual-action" role in radiation therapy, acting as a selective radiosensitizer for tumors and a radioprotector for healthy tissues. This phenomenon was notably observed in pancreatic cancer models and an initial Phase I human study. Results showed that intravenous infusions during radiation increased DNA damage and cell death within the tumor while simultaneously shielding the intestines from radiation-induced injury. These findings translated into improved progression-free and overall survival rates when compared to historical data.

The biological basis for this synergy lies in the production of hydrogen peroxide (H_2O_2). In the cancerous environment, H_2O_2 intensifies the destructive power of radiation; however, in normal tissues, vitamin C provides antioxidant protection. This dual effect effectively broadens the "therapeutic window," allowing for more aggressive treatment of the cancer with fewer systemic complications.

Clinical Applications in Radiotherapy

- Pancreatic Cancer: Concurrent use during radiation has been shown to reduce common side effects, such as intestinal damage, while potentially extending survival.[46]
- Glioblastoma: In trials involving newly diagnosed glioblastoma, adding high-dose ascorbate to standard radiotherapy and temozolomide was well-tolerated. It successfully reached the required millimolar plasma levels without causing dose-limiting toxicities, providing promising survival data that is currently being used to refine dosing for future research.

6.3. Immunotherapy Combinations

Beyond its direct effects on tumor cells, vitamin C is emerging as a powerful agent for enhancing cancer immunotherapy. It works by intensifying the body's natural antitumor defenses and restructuring the tumor microenvironment. Research suggests that high-dose ascorbate can significantly increase T-cell-mediated tumor suppression and improve the overall effectiveness of checkpoint blockade therapies.

Recent studies using lung cancer models have demonstrated that combining high-dose ascorbate with anti-PD-1 therapy leads to a more pronounced reduction in tumor growth. This synergy is driven by several immunological shifts:

- Increased Cytotoxicity: A rise in granzyme B production, which is essential for T-cells to kill cancer cells.
- Innate Immune Support: Enhanced expression of IL-12, a signaling molecule that activates the immune system.
- Environmental Shift: A transition from an immune-suppressive tumor environment to one that actively supports tumor clearance.

Modern immuno-oncology reviews suggest that pharmacological ascorbate may serve as a universal sensitizer, improving the outcomes of chemotherapy, radiation, and immunotherapy alike. This highlights the need for future clinical trials that incorporate both immune and redox-based biomarkers to better track how these combinations work in patients.

6.4. Mechanistic Basis for Synergy

The therapeutic power of pharmacological ascorbate lies in its ability to reach transient plasma levels of 10–20 mM following intravenous delivery. These high concentrations trigger the production of extracellular hydrogen peroxide (H_2O_2), which infiltrates tumor cells. Once inside, it compounds the DNA damage caused by traditional genotoxic treatments, effectively lowering the survival threshold of the cancer and breaking through mechanisms of drug resistance.

Key Synergistic Pathways

- Chemosensitization: When paired with agents like gemcitabine, vitamin C disrupts the tumor's energy production and redox balance. This metabolic interference allows for "dose-sparing"—achieving high levels of cancer cell death with lower, less toxic doses of chemotherapy—and improves responsiveness across different cellular states

(such as the epithelial-mesenchymal transition).

- Selective Radiosensitization: Vitamin C acts as a "double agent" during radiation. It intensifies the destructive pro-oxidant effects within the tumor while simultaneously providing antioxidant support to healthy tissues. This unique combination minimizes off-target injuries, like intestinal or skin damage, while maximizing the precision and intensity of tumor control.

6.5. Safety, Scheduling, and Clinical Integration

Data from both early-phase and randomized clinical trials consistently show that high-dose intravenous (IV) vitamin C is well tolerated by patients. When integrated into standard chemotherapy and radiation protocols, it typically results in only mild, infusion-related side effects rather than severe, dose-limiting toxicities. In many cases, patients actually report a better quality of life and a noticeable reduction in the overall burden of adverse events caused by their primary cancer treatments.

Clinical Implementation Guidelines

To achieve and sustain the necessary therapeutic exposure, specific practical parameters have been established:

- Dosing: Standard infusions range from 50 g to 100 g, with 75 g being the most common benchmark.
- Frequency: Infusions are typically administered two to three times per week.
- Timing: Careful scheduling around radiation and chemotherapy sessions is vital to maximize the sensitizing effects on tumor cells.
- Safety Screening: Routine medical screening, particularly for G6PD deficiency, is mandatory to prevent rare complications, alongside the monitoring of electrolytes and fluid balance.

Future Directions in Research

Modern clinical reviews advocate for a more personalized approach in future Phase II and III trials. Instead of a one-size-fits-all model, researchers are calling for studies that stratify patients based on their specific tumor genomics and unique immune/redox biomarkers. By incorporating pharmacodynamic endpoints—measuring how the body responds to the dose in real-time—scientists aim to more clearly link vitamin C exposure to specific biological mechanisms and long-term clinical benefits across different types of cancer.

7. Safety, Quality of Life, and Adverse Effects

High-dose intravenous vitamin C, known as pharmacological ascorbate, has established a strong safety record across numerous clinical trials involving patients with both early-stage and terminal cancer. Phase I studies indicate that doses as high as 1.5 g/kg per infusion are well-tolerated, typically causing only mild, temporary side effects such as nausea, chills, headaches, or increased urination. Notably, these studies have not identified severe dose-limiting toxicities. Beyond its basic safety, observational evidence suggests that IV vitamin C can actually lower the toxic burden of chemotherapy, which may help patients adhere more strictly to their primary treatment plans.

Quality of Life (QoL) and Palliative Benefits

Improving a patient's daily experience is a primary goal of adjunctive cancer care. Research consistently shows that IV vitamin C can significantly enhance physical, emotional, and cognitive functions. In terminal cases, patients have reported marked reductions in:

- Fatigue and Pain: Improving energy levels and comfort.

- Gastrointestinal Distress: Lowering instances of nausea and appetite loss.
- Symptom Management: Providing essential palliative support where standard treatments may be limited.

Risk Mitigation and Contraindications

While generally safe, certain medical conditions require strict screening to avoid complications:

- G6PD Deficiency: Patients with this genetic condition are at risk for hemolytic anemia (the breakdown of red blood cells) due to vitamin C-induced oxidative stress and must be screened before starting therapy.
- Renal Health: High doses may increase the risk of kidney stones in susceptible individuals; therefore, renal function should be monitored.
- Hemochromatosis: Because vitamin C increases iron absorption, it is contraindicated for patients with iron-overload disorders.
- Fluid Management: The volume of the IV infusion must be managed carefully to prevent fluid overload, particularly in patients with heart or kidney issues.

Interactions with Chemotherapy

A historical concern in oncology was that vitamin C's antioxidant properties might protect cancer cells from the oxidative damage intended by chemotherapy. However, modern data suggests the opposite: at the high concentrations achieved via IV, vitamin C acts as a pro-oxidant. This creates a dual benefit where normal tissues are shielded from toxicity, while cancer cells—which are uniquely vulnerable to oxidative stress—become more susceptible to the treatment. This complexity emphasizes why vitamin C must be administered in a controlled, clinical environment during multi-agent regimens.

In conclusion, while high-dose IV vitamin C offers a safe and effective way to improve patient quality of life and manage symptoms, success depends on rigorous patient screening (especially for G6PD) and a nuanced understanding of its biochemical interactions within the body.

8. Limitations and Controversies

Despite the growing interest in pharmacological ascorbate, its integration into standard oncology is hindered by several significant hurdles and ongoing debates. A primary concern is the inconsistency of clinical data; while early-stage trials often show positive trends, large-scale randomized controlled trials (RCTs) frequently fail to replicate these survival benefits. This discrepancy is often attributed to variations in patient populations, the timing of the intervention, and, most importantly, the route of administration.

The Antioxidant vs. Pro-oxidant Debate

A central point of contention is the "double-edged sword" nature of vitamin C. At standard doses, its antioxidant function may inadvertently protect cancer cells from the oxidative stress that chemotherapy and radiation aim to produce. While intravenous doses bypass this by acting as a selective pro-oxidant, the clinical community remains cautious, calling for more definitive evidence to prove that this doesn't lead to unintended treatment resistance.

Bioavailability and Practical Barriers

The "pharmacokinetic ceiling" of oral vitamin C remains a major limitation. Many failed trials relied on oral supplements, which cannot reach the millimolar concentrations needed to kill tumors. However, the shift to intravenous

administration introduces logistical challenges, requiring specialized equipment, high-grade clinical formulations, and strict medical oversight, which limits its accessibility in many healthcare settings.

Table 11: Summary of Challenges and Controversies in Vitamin C Oncology.

Category	Specific Limitation/Controversy	Impact on Clinical Use
Evidence Gap	Conflicting results between cohort studies and large RCTs.	Creates skepticism regarding overall survival benefits.
Duality of Action	Potential for antioxidants to interfere with ROS-mediated chemo.	Leads to concerns about reduced treatment efficacy.
Pharmacokinetics	Oral intake cannot reach cytotoxic plasma levels.	Explains negative results in oral-only clinical trials.
Patient Safety	Risks of hemolysis (G6PD deficiency) or kidney stones.	Requires mandatory pre-screening and monitoring.
Trial Quality	Small sample sizes and lack of placebo controls.	Makes it difficult to draw definitive, universal conclusions.
Standardization	Lack of uniform dosing and manufacturing guidelines.	Hinders the development of official clinical practice rules.

9. Future Directions

The future of vitamin C in oncology is focused on closing the gap between laboratory success and widespread clinical application. To maximize therapeutic benefits, research is shifting toward addressing the complexities of patient stratification, delivery methods, and standardized protocols. A primary objective is the execution of large-scale, high-quality randomized controlled trials. these studies are essential to pinpoint the most effective dosages, the best timing for administration, and the ideal combinations of therapies that harness pro-oxidant cytotoxicity without allowing antioxidant activity to interfere with conventional treatments.

A critical step in this evolution is the standardization of pharmacokinetic and pharmacodynamic markers. By creating a uniform way to measure how vitamin C moves through the body and interacts with tumor cells, the medical community can better compare data across different studies. This harmonization is key to accelerating the acceptance of vitamin C as a legitimate, evidence-based component of modern cancer care.

9.1. Biomarker Development and Patient Stratification

A major priority for future research is the identification of predictive biomarkers that can pinpoint which patients are most likely to respond to vitamin C therapy. Rather than a "one-size-fits-all" approach, evidence suggests that the molecular landscape of a tumor significantly influences its sensitivity. Key factors currently under investigation include specific genetic mutations—such as KRAS and BRAF—as well as the tumor's unique redox imbalance and epigenetic signatures.

By integrating advanced phenotyping techniques—including genomics, metabolomics, and detailed analyses of the immune microenvironment—clinicians hope to move toward a model of precision oncology. This would allow for highly personalized treatment plans, ensuring that vitamin C is utilized in combination regimens specifically tailored to the biological vulnerabilities of an individual’s cancer.

9.2. Nanotechnology and Advanced Delivery Systems

The use of nanotechnology to deliver vitamin C and its derivatives is a rapidly advancing frontier in oncology. By utilizing engineered nanoparticles, researchers aim to overcome the traditional limitations of bioavailability and rapid systemic clearance, effectively optimizing the therapeutic index of the treatment.

Enhancing Precision and Potency

Advanced nanocarriers offer several transformative advantages for vitamin C therapy:

- Selective Targeting: Nanoparticles can be designed to accumulate specifically within tumor tissues, sparing healthy cells and reducing off-target effects.
- Controlled Release: These systems allow for the sustained release of ascorbate, maintaining lethal concentrations within the tumor microenvironment over longer periods.
- Co-delivery Strategies: Nanocarriers facilitate the simultaneous delivery of vitamin C alongside traditional chemotherapy or immunotherapy, ensuring that both agents reach the same malignant cells at the same time.

9.3. Integration with Immunotherapy

The convergence of vitamin C's immunomodulatory properties with immune checkpoint inhibition represents one of the most promising frontiers in modern oncology. High-dose pharmacological ascorbate has been shown in preclinical models to act as a powerful catalyst for the immune system by:

- Boosting T-Cell Activation: Increasing the number and aggressive response of tumor-fighting cells.
- Dismantling Immune Suppression: Neutralizing the "cloaking" mechanisms tumors use to hide from the body's natural defenses.
- Synergizing with Blockade Therapies: Significantly enhancing the effectiveness of PD-1 and PD-L1 inhibitors.

While clinical trials exploring vitamin C as a partner to immunotherapy are still in their early stages, researchers believe this combination could be key to overcoming current resistance mechanisms and broadening the success of immuno-oncology across a wider range of patients.

9.4. Epigenetic and Metabolic Targeting

A deeper understanding of how vitamin C influences epigenetic remodeling and metabolic reprogramming provides new pathways for combination therapies. By pairing vitamin C with epigenetic drugs (such as DNA methyltransferase inhibitors) or metabolic inhibitors, clinicians may be able to:

- Promote Differentiation: Force malignant cells to mature into less aggressive forms.
- Trigger Apoptosis: Program cancer cells to self-destruct.
- Enhance Recognition: Make tumors more visible to the immune system.

Successfully targeting these pathways addresses the dual risks of drug resistance and relapse. However, the most critical step for future clinical design remains decoding the precise molecular "switch" that causes vitamin C to flip between its protective antioxidant role and its lethal pro-oxidant action.

9.5. Standardization and Regulatory Guidelines

To move vitamin C from a specialized adjunctive treatment to a widely adopted oncological standard, the development of universal clinical protocols is essential. This includes:

- Pharmaceutical-Grade Standards: Ensuring the consistency and purity of intravenous vitamin C preparations.
- Mandatory Screening: Establishing firm guidelines for G6PD deficiency testing to prevent patient harm.
- Regulatory Endorsement: Securing official approval based on rigorous Phase II and III trial data, backed by ongoing pharmacovigilance to track long-term safety.

CONCLUSION

Vitamin C represents a multifaceted, promising bioagent in the landscape of cancer prevention and treatment. Its biochemical duality as an antioxidant at physiological doses and a pro-oxidant at pharmacological concentrations underpins a complex yet exploitable mechanism of selective tumour cytotoxicity, epigenetic remodelling, and immune modulation. Epidemiological data consistently correlate adequate dietary vitamin C intake with decreased risks for multiple cancer types, reinforcing its potential role in chemoprevention, although supplementation beyond dietary sources remains controversial.

Clinically, high-dose intravenous vitamin C has demonstrated safety and tolerability across diverse solid tumours, with emerging evidence for survival benefits, reduced therapy-associated toxicities, and improved quality of life in combination regimens—particularly in pancreatic, ovarian, and glioblastoma cancers. Synergistic effects with chemotherapy, radiotherapy, and immunotherapy highlight vitamin C's potential to enhance conventional treatments and widen therapeutic windows. Nevertheless, significant limitations and controversies remain in dosing standardisation, bioavailability, and mechanistic nuances, necessitating rigorous future trials and biomarker-driven personalised approaches.

Technological advances such as nanoparticle-based delivery systems, improved molecular stratification, and integration with immune checkpoint inhibitors represent promising future directions that may augment vitamin C's therapeutic indices and broaden clinical applicability. Coupled with a strong safety record and demonstrated patient-centric benefits, vitamin C stands out as a potentially transformative adjunct in oncology. Ultimately, a clear understanding of its multifactorial biology, careful patient selection, and ethical clinical trial design are prerequisites to achieving conclusive evidence and formal guideline inclusion, ensuring vitamin C can be successfully integrated into comprehensive, multimodal cancer therapies.

REFERENCES

1. Alexander, M. S., Wilkes, J. G., Schroeder, S. R., Buettner, G. R., Wagner, B. A., Du, J., Gibson Corley, K. N., O'Leary, B. R., Spitz, D. R., Buatti, J. M., Cullen, J. J., & Allen, B. G., Pharmacologic ascorbate reduces radiation-induced normal tissue toxicity and enhances tumor radiosensitization in pancreatic cancer. Cancer Research, 2018; 78(24): 6838–6851.
2. Allen, B. G., Bodeker, K. L., Smith, M. C., Monga, V., Sandhu, S., Hohl, R., Carlisle, T., Brown, H., Hollenbeck, N., Vollstedt, S., Greenlee, J. D., Howard, M. A., Mapuskar, K. A., Seyedin, S. N., Caster, J. M., Jones, K. A., Cullen, J. J., Berg, D., Wagner, B. A., Buettner, G. R., TenNapel, M. J., Smith, B. J., Spitz, D. R., & Buatti, J. M., First-in-human phase 1 clinical trial of pharmacological ascorbate combined with radiation and temozolomide for newly diagnosed glioblastoma. Clinical Cancer Research, 2019; 25(22): 6590–6597.
3. Block, G., Vitamin C and cancer prevention: The epidemiologic evidence. The American Journal of Clinical Nutrition, 1991; 53(1 Suppl): 270S–282S.
4. Bodeker, K. L., Smith, B. J., Berg, D. J., Chandrasekharan, C., Sharif, S., Fei, N., Vollstedt, S., Brown, H., Chandler, M., Lorack, A., McMichael, S., Wulfekuhle, J., Wagner, B. A., Buettner, G. R., Allen, B. G., Caster, J. M., Dion, B., Kamgar, M., Buatti, J. M., & Cullen, J. J., A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer. Redox Biology, 2024; 77: 103375.
5. Brabson, J. P., Scully, S., & Sykes, D. B., Epigenetic regulation of genomic stability by vitamin C. Frontiers in

Genetics, 12, 675780. https://doi.org/10.3389/fgene.2021.675780Cao, X., Yi, Y., Ji, M., Liu, Y., Wang, D., & Zhu, H. (2025). The dual role of vitamin C in cancer: From antioxidant prevention to prooxidant therapeutic applications. Frontiers in Medicine, 2021; 12: 1633447.

6. Carr, A. C., & Cook, J., Intravenous vitamin C for cancer therapy—Identifying the current gaps in our knowledge. Frontiers in Physiology, 2018; 9: 1182.
7. Carr, A. C., Vissers, M. C., & Cook, J. S., The effect of intravenous vitamin C on cancer-and chemotherapy-related fatigue and quality of life. Frontiers in Oncology, 4, 283. https://doi.org/10.3389/fonc.2014.00283Chen, Z., Zhao, K., Wang, S., & Tang, H. (2022). Vitamin C intake and cancers: An umbrella review. Frontiers in Nutrition, 2014; 8: 812394.
8. Doseděl, M., Jirkovský, E., Macáková, K., et al., Vitamin C—Sources, physiological role, kinetics, deficiency, and toxicity. Nutrients, 2021; 13(2): 615.
9. Espey, M. G., Chen, P., Chalmers, B., Drisko, J., Sun, A. Y., Levine, M., & Chen, Q., Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Radical Biology and Medicine, 2011; 50(11): 1610–1619.
10. Fatoki, F. M., Akinyemi, E. K., & Phlips, S. A., Prediction of lungs cancer diseases datasets using machine learning algorithms. Current Journal of Applied Science and Technology, 2023; 42(11): 15–23.
11. Kim, H. S., Choi, Y., Ryu, H., Park, J., Yoon, S., & Lee, J., High-dose ascorbic acid synergizes with anti-PD1 therapy in lung cancer by enhancing antitumor immune responses. Frontiers in Immunology, 2025; 16: 1512605.
12. Kotamkar, S., Jha, R. K., & Bankar, N., A brief research on cancer. Journal of Pharmaceutical Research International, 2021; 33(38B): 323–329.
13. Kranjcec, B., Abdovic, S., & Topolcan, O., Effects of the combination of vitamin C with chemotherapy on the oxidative stress of cancer patients: A systematic review. Antioxidants, 2022; 11(2): 290.
14. Lee Chong, T., Wang, L., & Kim, H. J., Reprogramming the epigenome with vitamin C. Frontiers in Cell and Developmental Biology, 2019; 7: 128.
15. Lee, B., Oh, S. W., & Myung, S. K., Efficacy of vitamin C supplements in prevention of cancer: A meta-analysis of randomized controlled trials. Korean Journal of Family Medicine, 2015; 36(6): 278–285.
16. Lee, W. J., The prospects of vitamin C in cancer therapy. Immune Network, 2009; 9(5): 147–152.
17. Linus Pauling Institute, Oregon State University. (2025, August 10). Vitamin C.
18. Luo, J., Zhao, Z., & Zheng, S., Association between vitamin C intake and lung cancer risk: A meta-analysis. Scientific Reports, 2014; 4: 6161.
19. Lykkesfeldt, J., Carr, A. C., & Tveden-Nyborg, P., The pharmacology of vitamin C. Pharmacological Reviews, 2025; 77(2): 100043.
20. Ma, Y., Chapman, J., Levine, M., Polireddy, K., Drisko, J., & Chen, Q., High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Science Translational Medicine, 2014; 6(222).
21. Maekawa, T., Miyake, T., Tani, M., & Uemoto, S., Diverse antitumor effects of ascorbic acid on cancer cells and the tumormicroenvironment. Frontiers in Oncology, 2022; 12: 981547.
22. Magrì, A., Germano, G., Lorenzato, A., Lamba, S., Chilà, R., Montone, M., Amodio, V., Ceruti, T., Sassi, F., Arena, S., & Bardelli, A., High-dose vitamin C enhances cancer immunotherapy. Science Translational Medicine, 2020; 12(532): eaay8707.

23. Maurya, V. K., Mandal, S., & Tripathi, J., Vitamin C fortification: Need and recent trends in technologies. Frontiers in Nutrition, 2023; 10: 1229243.
24. Mayo Clinic. (2025, August 13). Vitamin C.
25. Mikkelsen, S. U., Gillberg, L., Lykkesfeldt, J., & Grønbæk, K., The role of vitamin C in epigenetic cancer therapy. Free Radical Biology and Medicine, 2021; 170: 179–193.
26. Mussa, A., Mohd Idris, R. A., Ahmed, N., Ahmad, S., Murtadha, A. H., Tengku Din, T. A. D. A. A., Yean, C. Y., Wan Abdul Rahman, W. F., Mat Lazim, N., Uskoković, V., Hajissa, K., Mokhtar, N. F., Mohamud, R., & Hassan, R., High-dose vitamin C for cancer therapy. Pharmaceuticals (Basel, Switzerland), 2022; 15(6): 711.
27. Ngo, B., Van Riper, J. M., Cantley, L. C., & Yun, J., Targeting cancer vulnerabilities with high-dose vitamin C. Nature Reviews Cancer, 2019; 19(5): 271–282.
28. Ou, J., Zhu, X., Chen, P., Du, Y., Lu, Y., Peng, X., Bao, S., Wang, J., Zhang, X., Zhang, T., & Pang, C. L. K., A randomized phase II trial of best supportive care with or without hyperthermia and vitamin C for heavily pretreated, advanced, refractory non-small-cell lung cancer. Journal of Advanced Research, 2020; 24: 175–182.
29. Paller, C. J., Zahurak, M. L., Mandl, A., Metri, N. A., Lalji, A., Heath, E., Kelly, W. K., Hoimes, C., Barata, P., Taksey, J., Garrison, D. A., Patra, K., Milne, G. L., Anders, N. M., Nauroth, J. M., Durham, J. N., Marshall, C. H., Markowski, M. C., Eisenberger, M. A., Antonarakis, E. S., Levine, M., High-dose intravenous vitamin C combined with docetaxel in men with metastatic castration-resistant prostate cancer: A randomized placebo-controlled phase II trial. Cancer Research Communications, 2024; 4(8): 2174–2182.
30. Pawlowska, E., Sokolowska, J., Blasiak, J., & Szczepanska, J., Pro-and antioxidant effects of vitamin C in cancer. Oxidative Medicine and Cellular Longevity, 2019; 2019: 7286737.
31. Pinkerton, J. V., Jr., et al., Intravenous vitamin C, Health professional version. National Cancer Institute. H, 2013.
32. Renner, O.,Prochnow, H., Goenner, F., & Tichy, A., Parenteral high dose ascorbate—A possible approach for treatment of glioblastoma. International Journal of Oncology, 2021; 58(6): 1–12.
33. Schoenfeld, J. D., Alexander, M. S., Waldron, T. J., Sibenaller, Z. A., Spitz, D. R., Buettner, G. R., Allen, B. G., & Cullen, J. J., Pharmacological ascorbate as a means of sensitizing cancer cells to radio-chemotherapy while protecting normal tissue. Seminars in Radiation Oncology, 2019; 29(1): 25–32.
34. Stephenson, C. M., Levin, R. D., Spector, T., & Lis, C. G., Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 2013; 72(1): 139–146.
35. Sun, L., Yuan, C., Ma, X., Zhang, H., Zhang, X., & Hu, Y., Smart nanoparticles for cancer therapy. Signal Transduction and Targeted Therapy, 2023; 8(1): 238.
36. Talib, W. H., Shaker, M. A., Farhan, F., & Khasawneh, M., Role of vitamins A, C, D, E in cancer prevention and therapy. Frontiers in Nutrition, 2024; 11: 1281879.
37. Villagran, M., Ferreira, J., Martorell, M., & Mardones, L., The role of vitamin C in cancer prevention and therapy: A literature review. Antioxidants, 2021; 10(12): 1894.
38. Villagran, M., Ferreira, J., Martorell, M., & Mardones, L., The role of vitamin C in cancer prevention and therapy: A literature review. Antioxidants, 2021; 10(12): 1894.
39. Wang, G., Li, X., Zhao, J., & Li, J., In vitro andin vivoassessment of high-dose vitamin C on murine tumor cells. Experimental and Therapeutic Medicine, 2016; 12(5): 3412–3418.
40. Welsh, J. L., Wagner, B. A., van't Erve, T. J., Zehr, P. S., Berg, D. J., Halfdanarson, T. R., Yee, N. S., Bodeker,

K. L., Du, J., Roberts, L. J., Drisko, J., Levine, M., Buettner, G. R., & Cullen, J. J., Pharmacological ascorbate with gemcitabine for the control of metastatic and node positive pancreatic cancer (PACMAN): Results from a phase I clinical trial. Cancer Chemotherapy and Pharmacology, 2013; 71(3): 765–775.

41. Woldeselassie, M., & Tamene, A., Therapeutic controversies over use of antioxidant supplements during cancer treatment: A scoping review. Frontiers in Nutrition, 2024; 11: 1480780.
42. Yao, Y., Zhou, Y., Liu, L., Xu, Y., Chen, Q., Wang, Y., Wu, S., Deng, Y., Zhang, J., & Shao, A., Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Frontiers in Molecular Biosciences, 2020; 7: 193.
43. Yeom, C. H., Jung, G. C., & Song, K. J., Changes of terminal cancer patients' health-related quality of life after high dose vitamin C administration. Journal of Korean Medical Science, 2007; 22(1): 7–11.
44. Zaher, A., Miller, A. C., & El-Mowafy, A. M., Pharmacological ascorbate as a novel therapeutic strategy to enhance cancer immunotherapy. Frontiers in Immunology, 2022; 13: 989000.
45. Zasowska-Nowak, A., Nowak, P. J., & Ciałkowska-Rysz, A., High-dose vitamin C in advanced-stage cancer patients. Nutrients, 2021; 13(3): 735.
46. Zhong, J., Li, P., Zheng, F., Li, Y., Lu, W., Chen, H., Cai, J., Xia, D., & Wu, Y., Association between dietary vitamin C intake/blood level and risk of digestive system cancer: A systematic review and meta-analysis of prospective studies. Food & Function, 2024; 15(16): 8217–8237.